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SUMMARY
A FRONTIERS objective is to extend operations research (OR) into new areas such as
sustainability research and social marketing. This project marks a departure into these
areas.
CEMOPLAF of Quito, Ecuador sells reproductive health products to pharmacies and
other outlets to contribute to the sustainability of the not-for-profit agency. CEMOPLAF
lacked basic information regarding the program’s profitability, niche, and quality. OR to
provide this information included a financial analysis of the marketing program and two
market research studies. Each study included a capacity building component so that
CEMOPLAF could conduct similar studies in the future without technical assistance. A
regional conference attended by non-governmental organizations (NGOs) was also
included. The conference objective was to share sustainability tools and lessons learned.
The Commercial Market Strategies (CMS) project co-sponsored the conference.
Marketing Project Profitability Analysis: The study found that the marketing program
was profitable during the calendar year 1998, generating $103,000 in net profits. Return
on sales revenue was 10 percent. The condom brand Protektor brought in the most
revenue of any product, and contributed the highest total gross profits. Protektor’s
dominance was due to high sales volume, since the product is near to the bottom of the
list of net revenue per unit sold. Half of the sales force was responsible for nearly all of
the profits, and most of these agents worked in Quito-Guayaquil. Major
recommendations implemented by CEMOPLAF included shifting from sales revenue to
gross profit as an indicator of sales agent success, and a change from a salary-based
compensation system to a more heavily commission-based compensation system for sales
agents. Other important long-term impacts of this study include: (a) SM executives
learned to use the tools introduced in this study to routinely analyze financial
performance from a profitability perspective; and (b) sales agents now have access to
information for tracking unit profit margins, trends in sales volume, and the financial
performance of their own regions.
Marketing Project Client Profile: The study was conducted in a sample of pharmacies in
five cities. Results indicate that purchasers of CEMOPLAF contraceptives are of lower
socio-economic status than are purchasers of other contraceptive brands, and of
purchasers of non-contraceptive products in the pharmacies studied. Information on nonCEMOPLAF products purchased by customers was also obtained from the study, as was
information on products that were frequently sought but also frequently out of stock in
the pharmacies. This data helped CEMOPLAF decide to market higher margin, nonreproductive health products (including those frequently out of stock) directed at the
pharmacies’ more affluent clients.
Quality of Information Provided to CEMOPLAF Customers: Mystery shoppers
purchased CEMOPLAF oral contraceptives, DMPA and pregnancy tests from a
representative sample of pharmacies. This study revealed that pharmacists behave very

much like clinical providers of family planning methods; they provide clients with
method use instructions, but little or no information about side effects and
contraindications. However, information on these aspects of method use was increased
when clients asked specific questions of the pharmacists. Due to lack of funds, the
recommended intervention to increase information transfer - posters reminding clients to
ask the provider about contraindications and side-effects - could not be implemented.
Capacity Building Activities: As a result of the financial analysis, CEMOPLAF
marketing managers learned to gather and use profit data to make decisions regarding
individual sales agents, specific products and overall program direction. FRONTIERS
assistance also included three workshops for 28 program staff on market segmentation,
sales techniques, and billing and receiving. A local expert taught each workshop.
CEMOPLAF research staff learned to conduct point of purchase surveys, mystery client
studies, and financial analyses. Other agency staff gained experience as interviewers and
mystery clients, leaving the agency with the infrastructure needed to conduct future
market research.
Latin American Regional Conference on Sustainability and Social Mission: More than 80
individuals registered to attend the conference. They represented over 40 family
planning organizations, research organizations, pharmaceutical companies, and donors.
The conference objectives were to:
• Share sustainability research and lessons learned;
• Share experiences of NGOs that have attempted to improve the sustainability of
programs while maintaining their commitment to social mission; and
• Provide NGOs and companies that market reproductive health products the
opportunity to explore the possibility of commercial agreements.
Evaluation of the conference was positive, with almost 90 percent of participants rating it
as “useful” or “very useful.” CMS and FRONTIERS are in the process of planning a
similar conference for Africa.
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INTRODUCTION
Operations research (OR) has played an important role in all types of family planning and
reproductive health service delivery modalities with the exception of social and commercial
marketing programs where research has been limited mainly to market surveys. The current
movement towards sustainability is causing social marketing (SM) programs to examine issues
like profitability, productivity and quality. This provides an opportunity for extending OR into
the social marketing of reproductive health products and services.
CEMOPLAF of Quito, Ecuador is an excellent laboratory for introducing OR into social
marketing. The agency is experienced in operations research and uses it in making important
program decisions. CEMOPLAF is a leader in sustainability activities in Latin America, and its
staff is frequently called upon by other organizations in the region to provide technical
assistance. Finally, the agency has a rapidly growing social marketing program that accounts for
36 percent of agency revenues. CEMOPLAF is depending on SM to become the major force in
agency sustainability, and wishes to use OR to both improve profitability and quality and
increase program scope.
FRONTIERS initiated a long-term relationship with the CEMOPLAF commercial marketing
program with a two and a half year (February 1999 – August 2001) project that included both
diagnostic studies and capacity building activities. Three studies were conducted: (1) an
assessment of program profitability and productivity; (2) a determination of the profile of retail
purchasers of CEMOPLAF products; and (3) an evaluation of the quality of information
provided to retail purchasers of SM contraceptives. The diagnostic studies are intended to lead
to a subsequent round of intervention research to improve productivity, introduce new products
and improve the quality of information given to retail purchasers. Capacity building activities
included marketing seminars for SM project staff (none of whom were marketing professionals),
and training in the design, conduct and analysis of mystery client research. Finally, a regional
seminar on sustainability for not-for-profit reproductive health programs, co-sponsored with the
USAID funded Commercial Market Strategies (CMS) project was held in Ecuador in May 2001.
This final report includes information on the three research projects conducted by CEMOPLAF
as well as on the capacity building activities and the regional seminar.
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STUDY I: A FINANCIAL ANALYSIS OF THE CEMOPLAF
SOCIAL MARKETING PROGRAM
Author: John Bratt
I. Introduction
A. Background
Reproductive health programs in developing countries face a major challenge: to provide a
greater variety of products and services to a rapidly increasing number of users. This challenge
must be met in the context of stagnant or decreasing donor funding. One strategy for providing
more services to more people in the face of scarce resources is to shift clients out of highly
subsidized services (such as those provided by government programs) to social marketing
programs, and ultimately to the commercial sector.
Social marketing has become an increasingly prevalent mechanism for delivering family
planning and reproductive health services. In the Latin America and Caribbean (LAC) region,
for example, virtually every country receiving USAID funding in recent years has a social
marketing program. These programs occupy a middle ground between the public and for-profit
sectors. They serve individuals with sufficient resources to pay something for services, although
not full commercial sector prices.
Because of sustainability concerns, many social marketing programs are now pursuing strategies
to add for-profit product lines in order to cross-subsidize products that are sold at subsidized
prices, or even to cross-subsidize clinical or community based (CBD) programs. But little
research exists to guide program managers in deciding how to proceed. For example, in almost
15 years the Latin American Operations Research Projects (INOPAL) conducted only three
studies with social marketing programs, while carrying out approximately 150 studies with
clinical and CBD programs. SM programs have focused their research activities on market
surveys, but little sustainability or quality improvement research has been published.
B. Program Setting
CEMOPLAF is a non-governmental (NGO), not-for-profit organization that operates several
reproductive health programs throughout Ecuador, including 21 clinical centers, a rural CBD
program, and special programs for adolescents, commercial sex workers, men and indigenous
groups. The organization has become known as a leader in sustainability activities in Latin
America. CEMOPLAF recovers approximately 80 percent of total operating costs through client
fees, and staff are consultants to other LAC reproductive health programs. CEMOPLAF also
uses operations research as a routine decision making tool.
In 1996 CEMOPLAF launched its first social marketing project; by 1998 social marketing
became the largest single source of locally-generated funds, accounting for approximately 36
percent of gross revenue ($67,000 per month). The SM project sells contraceptive and
reproductive health products to pharmacies, physicians, other distributors and non-traditional
outlets including liquor stores, hotels, motels and brothels. At the end of 1998 the SM project
5

was selling 36 different products, most of which were purchased locally from pharmaceutical
supply houses.1 In terms of unit sales, the most important are pills (234,000 cycles per year),
condoms (800,000 packages of three per year), injectable contraceptives (100,000 doses per
year), and home pregnancy tests (40,000 tests per year). SM executives plan to gradually expand
the list of products offered.
In 1998 the project employed 29 full and part-time workers and deployed sales agents in 14 of
the 16 cities where CEMOPLAF operates clinics. But rapid growth had left the project with
inadequate infrastructure and procedures, particularly for analyzing financial performance.
Plans existed for introducing a computerized management information system, but in 1998
project staff were still using a manual system, making basic financial analysis very
cumbersome. Moreover, the project had not yet identified basic indicators for assessing overall
profitability, productivity of its sales force, or the contribution of specific products to
profitability.
II. Objectives
The specific objectives of this study were to:
•
•

Conduct a financial analysis to measure profitability of the social marketing project and of
individual sales agents; and
Build capacity for financial analysis within the program so that future studies could be done
with minimal external assistance.

The study contributed to the achievement of FRONTIERS' Intermediate Result 3, "capacity for
problem solving enhanced within organizations." Prior to the study, decision making in the
CEMOPLAF social marketing program was not supported by information on profitability or
productivity. It is expected that future decisions will be informed by data on profitability and
productivity. The project also contributed to USAID/Ecuador's Intermediate Result 1,
"increased sustainability of family planning NGO partners" by strengthening CEMOPLAF's
financial control over its SM project, and by explicitly placing strategic emphasis on profitability
as the main measure of success.
III. Methods
The unit of analysis in this study was the social marketing sales agent. We used a “bottom-up”
costing approach to identify and value all of the resources used by sales agents and other
CEMOPLAF staff to market SM products. Detailed information follows on methods used to
cost different types of resources, and also to calculate program revenues generated by each sales
agent.

1

USAID continues to donate contraceptive methods to the program, including condoms, pills, IUDs and injectables.
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A. Program Costs
1. Contraceptives, medicines and other products
CEMOPLAF purchases most SM products from local suppliers of pharmaceuticals. In
Ecuadoran commerce, it is common practice for suppliers to deliver more units than a customer
actually purchases (usually 10 – 20 percent more) as an incentive for future business. These
bonus units reduce CEMOPLAF’s actual per-unit product cost below the official price negotiated
with suppliers. SM accountants reviewed purchase records and calculated unit cost for each
product by dividing the total amount paid by the number of units entered into inventory. In this
way, unit product costs were adjusted downward to reflect the value of the “bonus units” added
to the order by the supplier. Because of volatility in the Ecuadoran economy, product costs were
increasing at different rates throughout 1998. It was therefore necessary to calculate unit product
costs separately for each month of the year.
Estimated unit costs of donated contraceptives were imputed by determining the cost of
purchasing similar products and then adding labor and materials costs to repackage the products.
2. Sales agent compensation
CEMOPLAF accountants provided information on salaries, benefits and sales commissions paid
to sales agents in 1998. Total compensation per agent was calculated by summing nominal
salary, the 12 separate benefit categories required by Ecuadoran law, and sales commissions.
3. Administrative support in CEMOPLAF clinics
Sales agents in all regions except Quito are physically situated in small offices located within
CEMOPLAF clinics.2 Administrative staff in these clinics provide varying levels of supervision
and accounting support to sales agents. We visited each clinic and conducted interviews to
determine the proportion of time spent by individual staff members assisting the SM program.
The cost of this time was calculated for each administrative staff person by multiplying total
annual compensation by the percentage of annual work time dedicated to SM.
4. Other operating costs
Sales agents incur a range of other costs in the course of marketing SM products. These include
costs of transport, per diem, product-specific advertising, etc. Moreover, the SM program
invests resources annually to organize training seminars and meetings for staff. Information on
these costs was provided by SM accountants. When feasible, costs corresponding to specific
sales agents were taken directly from expenditure records (for example, transport and perdiem,
office supplies); costs of resources that benefit the entire SM program (training, advertising)
were divided equally among the 25 sales agents working in 1998.

2

In Quito, the 10 sales agents occupy space that is contiguous with the Social Marketing executive office.
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5. Infrastructure and equipment
Sales agents were assigned a portion of building rent, utilities and housekeeping costs
corresponding to the percentage of the CEMOPLAF clinic floor space occupied by the SM
office. In facilities owned by CEMOPLAF, we calculated an estimate of equivalent rental value
per square meter by averaging the rental charges per square meter in leased facilities.
Annualized costs of office furniture were estimated under the assumption that each sales agent
used a basic grouping of a desk, a chair and a filing cabinet. Sales agents also use personal
computers for inventory management, record-keeping and reporting. In Quito, each sales agent
has exclusive use of a PC, and therefore was assigned the entire annualized cost. In other sites
computer resources are shared with clinic staff. Our approach was to assign a portion of the
annualized computer cost corresponding to the percentage of time that clinic administrative staff
dedicated to the SM program, since the time spent was mainly used to input SM data into the
computer. Finally, the SM program owns a vehicle that is used exclusively to support the efforts
of the ten sales agents working in Quito. The cost of this vehicle was annualized, and divided
equally across these ten sales agents.
B. Sales Revenue
The SM program charges its customers (pharmacies and physicians) a negotiated price for each
unit sold, and also offers in-kind bonuses (usually 10 percent) to encourage future sales.
Program accountants provided price lists for each product, by month. Sales revenue for each
month was calculated by multiplying the corresponding unit price for each product by the
number of units sold.
IV. Results
A. Overall Profitability
The objective of the social marketing program is to produce profits that can be used to support
other CEMOPLAF programs. Table 1 provides information on total revenue, total costs and net
profit for 1998. Sales of products generated revenues of 5.6 billion sucres (approximately
US$1.3 million at the average 1998 exchange rate). CEMOPLAF paid over 3.9 billion sucres
(US$715,000) to acquire these products from suppliers, leaving a gross profit of nearly 1.7
billion sucres (US$300,000). Costs of running the program – including sales, marketing and
management – totaled 1.1 billion sucres (US$198,000). Net profit for 1998 was 563 million
sucres (US$103,000), representing a 10 percent return on sales volume.
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Table 1: Calculation of Net Profit, CEMOPLAF Social Marketing Program, 1998
Millions of 1998 Sucres
Sales Revenue
Cost of Goods Sold

5,631
3,967

Gross Profit

1,664

Other Program Costs
Personnel
Training
Advertising
Other Recurrent Costs
Equipment
Infrastructure
Program Overhead

612
23
94
95
33
79
165

Total Other Program Costs

1,101

Net Profit

563

B. Uses of Program Income
Figure 1 consolidates information in Table 1 to provide a graphical representation of how
CEMOPLAF used the income generated by the SM program in 1998. Seventy percent of sales
revenue was used to cover product costs. Program costs (including staff, supplies, advertising
and other costs) and program overhead consumed an additional 20 percent, leaving a profit
margin of 10 percent.

Figure 1: Uses of Social Marketing Income,
CEMOPLAF 1998
10%
3%
6%
Cost of Goods Sold
Personnel Costs
Other Direct Costs

11%

Program Overhead
Net Profit

70%
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C. Differences in Net Revenue by Product
In 1998 the SM product list included 36 different items, of which 19 were contraceptive
methods.3 Table 2 presents information on net revenue per unit for a subset of products. Net
revenue is defined as sales revenue minus product cost, and represents the margin earned from
each unit of sales that is available to cover other program costs. Net revenue varies substantially,
from a high of US$4.00 to a low of US$-0.02; average net revenue per unit is US$1.46. The
highest-selling brands tend to be those with lower per-unit margins, such as the Protektor
condom brand and LoFemenal oral contraceptives.
Table 2: Net Revenue per Unit for Selected Social Marketing Products, in 1998 Sucres
($US1 = 5450 S/.)
Top Five
Clamox cream
Mobic 15
Gynera CD
Marvelon
Clamox
Bottom Five
Protektor
Copper T 380A
LoFemenal
Nordette MD
Conceptrol
Average of all Products

Net Revenue per Unit
(US$ in parentheses)
21,840
20,400
19,748
18,450
18,159

(4.00)
(3.74)
(3.62)
(3.39)
(3.33)

2,412 (0.44)
1,726 (0.32)
1,542 (0.28)
936 (0.17)
- 95 (-0.02)
7,936 (1.46)

D. Profitability by Region
Approximately half of the SM sales agents work in either Quito or Guayaquil (the two major
urban areas of Ecuador), while the remaining agents work in smaller cities. Figure 2 shows
differences in productivity and profitability between the two regions. The lighter-shaded bar
represents gross profit, which equals sales revenue minus product costs (the same concept as net
revenue, only on an aggregate basis). The darker bar represents program costs, which equal total
SM costs excluding product costs. Agents working in Quito–Guayaquil produced nearly twice
as much gross profit as agents working in smaller cities, and accounted for more than 80 percent
of SM total net profits (shown by the difference between the gross profit and and program cost
bars).

3

These methods included 11 brands of OCs, five formulations of injectables, one brand of condoms, an IUD and a
contraceptive foaming tablet.

10

Millions of Sucres

Figure 2: Gross Profit and Non-product Costs of Social Marketing
Activities, by Region
(in 1998 sucres)
1500
1000
500
0
Quito + Guaya (n=13)

Other (n=12)
Region

Gross Profit

Non-product Costs

Differences between the two regions in productivity and profitability are related to sales volume
and to a lesser degree, composition of sales. All agents incur the same product costs, and
program costs are similar between the two regions. The key factor is gross profit; each agent
must produce approximately S/. 45 – 50 million (US$8,200 – $9,200) in gross profit in order to
break even.4 Gross profits can be increased by selling more products overall (sales volume) or
selling more of the most profitable products (composition of sales). Since the Quito-Guayaquil
region has a larger number of potential SM customers (pharmacies and physicians) and a more
diverse and commercialized market, it is easier for sales agents to generate gross profits (and
therefore net profits) in this region.

E. Profitability of Sales Agents
Figure 3 presents information on profitability of CEMOPLAF’s 25 sales agents. Each data point
represents one sales agent, and points are divided according to the two main regions: black
diamonds correspond to agents working in Quito-Guayaquil, and gray dots represent agents
working in other cities. The diagonal line shows all possible points where the agent “breaks
even”, i.e. where gross profit (sales revenue minus product cost) exactly equals program costs.
Points lying above the diagonal line indicate profitable sales agents. All but two of the QuitoGuayaquil sales agents earned net profits, while the majority of agents working in other cities
either lost money or earned small net profits.5

4

Gross profit is more useful as an indicator of productivity than sales revenue, because unit profit margins vary
substantially across products. As an example, consider the difference between two agents: one sells US$20,000 in
low-margin products, and generates gross profits of US$5,000; the other sells US$15,000 in high-margin products
and generates gross profits of US$7,000. The first agent produces more sales revenue, but the second agent
generates more net revenue.
5
Notable exceptions included sales agents in Riobamba (Jaramillo), Latacunga (Mayorga), and Santo Domingo
(Aguirre).
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Figure 3: Profitability of Individual Sales Agents, by Region,
CEMOPLAF 1998 (in millions of sucres)
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V. Conclusions and Recommendations
A. Conclusions
1. The social marketing project was profitable during the calendar year 1998, generating
$103,000 in net profits to be used by CEMOPLAF management to support other
activities. Return on sales revenue was 10 percent. We cannot say how this result
compares with financial performance of other SM programs because our literature
searches found no references to other studies on profitability of social marketing. But
even if such studies do exist, it is unlikely that results would be comparable because of
the economic cost focus used in our study.
2. The condom brand Protektor brought in the most revenue of any product, and contributed
the highest total gross profits. Protektor’s dominance was due to high sales volume, since
the product is near to the bottom of the list of net revenue per unit sold.
3. Half of the sales force is responsible for nearly all of the profits, and most of these agents
work in Quito-Guayaquil. Seven of 25 agents lost money.
4. Other important long-term impacts of this study include: (a) SM executives now have the
tools to analyze financial performance from a profitability perspective; (b) sales agents
will have access to better information for tracking unit profit margins, trends in sales
volume, and the financial performance of their own regions.
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B. Recommendations
1. The SM program should use gross profit as the key indicator of productivity for sales
agents. Gross profit is a better indicator of success than sales revenue, because sales
revenue does not account for product costs.
2. The SM program should evaluate current compensation policy for sales agents. Sales
bonuses range from 0% to 10 percent of salaries, with most sales agents clustered in a 1 –
3 percent band. It is unlikely that this bonus structure serves as a real incentive to agents
to sell more products. One idea would be to test an alternative compensation policy
where fixed salaries were substantially reduced, and sales agents were given opportunity
to earn substantial bonuses on gross profit.
3. The SM program should assess whether some of the smaller cities have a large enough
market to justify a dedicated SM presence, and consider eliminating or consolidating
sales areas.
4. The SM program should routinely collect, analyze and distribute information similar to
the data generated in this study. For example, sales agents should have current
information on net revenue by product, to know which products contribute the most to
profitability. Also, the SM program could make annual projections of non-product costs
for each sales agent (i.e., salary, transport, training, etc.) and then provide feedback to
sales agents on gross profits generated each month. Such a system would allow SM
management and each sales agent to track progress toward the break-even point.

13

STUDY II: MARKET ASSESSMENT FOR CEMOPLAF
PRODUCTS: CUSTOMER PROFILE
Authors: Dr. Laura C. Altobelli and Ana María Buller

I. Introduction
Social marketing is recently becoming recognized as an important channel for delivering family
planning and reproductive health services. It is a service-delivery strategy that has developed out
of the increasing demand for these services in the face of ever decreasing donor support. The
strategy involves shifting clients from government programs to partially subsidized social
marketing programs, and eventually to the commercial sector. Target clients are those who have
sufficient resources to pay something for services, although not full commercial sector prices. In
order to strengthen program sustainability, social marketing programs are now moving more into
commercial marketing by adding for-profit product lines in order to cross-subsidize products or
services that are sold at lower, subsidized prices.
CEMOPLAF of Quito, Ecuador is a private non-profit organization that provides reproductive
health services and products. The organization has grown to include 21 reproductive health
clinical centers, a rural CBD program, and special programs for adolescents, men, and
indigenous groups in 14 cities of Ecuador. In the area of program sustainability, CEMOPLAF
serves as a model for Latin America. Over 80 percent of CEMOPLAF costs are recuperated.
The largest portion of cost-recovery comes from social marketing activities. CEMOPLAF sells
contraceptive and reproductive health products to pharmacies, physicians, other distributors, and
non-traditional outlets including liquor stores, hotels, motels and brothels.
Within FRONTIERS’ global research agenda in sustainability, CEMOPLAF has been identified
as a key program for developing and conducting operations research in social marketing for
sustainability. CEMOPLAF wishes the program to become more commercial and capable of
generating income that will be used to subsidize other projects. To do so, CEMOPLAF will have
to build market share, add products, and expand into new markets. One of the steps for
CEMOPLAF to reach this goal is to better understand its products’ market share, the size of the
market for them, the socio-demographic profile of the current and potential purchasers of its
products, and other aspects including analyses of finances and quality of services.
The present document is a report on a market assessment study conducted to profile the
customers in commercial pharmacies where CEMOPLAF products are sold.

II. METHODOLOGY
We conducted point of purchase interviews in five cities with the largest market for CEMOPLAF
products: Quito, Guayaquil, Santo Domingo de los Colorados, Riobamba, and Ambato.
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A. Sample Selection
Sampling was done in two stages. A random sample of retail outlets selling CEMOPLAF
projects was drawn in each of the five cities. The number selected was roughly proportional to
the city’s population: 15 in Quito, 15 in Guayaquil, 10 in Santo Domingo, 5 in Riobamba, and 5
in Ambato for a total sample of 50 retail pharmacies. The sample in each city was stratified by
size of the pharmacy (large, medium, and small), determined by the average number of
customers per day.1 All persons exiting the selected pharmacies during pharmacy hours were
interviewed for a period of five consecutive days. All exiting customers who had made a
purchase in the pharmacy were asked to respond to the full questionnaire.2 The total number of
interviews of purchasing customers was 8,942.

B. Data Collection
Interviewers were CEMOPLAF personnel who had received prior training in interviewing
techniques. The questionnaire consisted primarily of closed-ended questions. Information was
collected on the interviewee’s sociodemographic characteristics, home and work location, reason
for purchasing in that particular pharmacy, medicine or product purchased that day, intended
recipient, ability to find all desired products, and those that had not been found.

III. Results
A. Socioeconomic Characteristics of Study Population
The socioeconomic characteristics of the study participants differed among the five cities, as
shown on Table 1. Education was positively associated with size of the city. Guayaquil had the
best-educated pharmacy clientele at 77.2 percent with secondary or higher education, followed
by Quito with 68 percent. The smallest city studied, Ambato, had the lowest percentage with
secondary or higher education (59.5%), as well as the highest proportion of clients with no
formal education (8%). Educational level is important when considering what type of
advertising and promotion is most effective.
Pharmacy clients had a median age of 33 years, though the distribution in each city varied.
Santo Domingo had a significantly lower proportion of persons over 45 than the other four cities.
This has implications for the types of pharmaceutical products they would be likely to purchase.
In all cities, females were more likely than males to be pharmacy purchasers. Size of city was
associated with male purchasing, ranging from a high of 48 percent male purchasers in
Guayaquil to a low of 39.1 percent male in Riobamba (Table 1).

1

The sample of pharmacies utilized was the same as that used for the mystery client study.
The first day of data collection, interviewees received a small incentive gift for their participation. This was
immediately identified as a stimulus for repeat purchases, and the practice was stopped for the remainder of the
study.
2
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Percentage of married or in-union pharmacy users ranged from 62 percent in Guayaquil to 71.1
percent in Ambato. The remainder was single or had ‘other’ civil status.
Interviewees reported up to three different products purchased. If any one was a CEMOPLAF
product, the person was coded as a CEMOPLAF purchaser. The highest proportions of
CEMOPLAF product buyers were in Santo Domingo with 11.7 percent and Riobamba with 8.9
percent. The lowest percentage (3.9%) was in Guayaquil.

Table 1: Characteristics of Study Population in Pharmacies by City
Characteristics of users
Education
None
Primary
Secondary
Superior
Age Group
< 15
15 - 24
25 - 34
35 - 44
45 or more
Sex
Female
Male
Marital status
Has partner
No partner
Source of products purchased
CEMOPLAF product
Other commercial product
N=

CITY*
Quito

(%)

Guayaquil (%)

Sto. Domingo (%)

Riobamba (%)

Ambato (%)

2.4
29.7
44.6
23.4

2.4
20.4
54.0
23.2

3.2
41.8
49.1
5.9

3.8
32.1
40.8
23.3

8.0
42.5
30.4
29.1

6.9
21.9
23.6
21.7
25.9

3.5
19.8
27.5
24.8
24.4

4.4
25.8
28.5
26.9
14.5

4.5
20.4
24.8
21.7
28.7

5.5
20.3
22.7
21.0
30.5

56.0
44.0

51.8
48.2

56.8
43.2

60.9
39.1

58.2
41.8

66.3
33.7

62.0
38.0

69.2
30.8

67.2
32.8

71.1
28.9

6.3
93.7

3.9
96.1

11.7
88.3

8.9
91.1

6.3
93.7

2993

2675

586

942

1746

* Quito – Capital of Ecuador in Andes mountains.
Guayaquil – Principal commercial/shipping center for Ecuador on coast.
Santo Domingo – Medium size provincial capital on inland coast.
Riobamba – Medium size provincial capital in Andes mountains.
Ambato – Small provincial capital in Andes mountains

1. Profile of Pharmaceutical Purchasers - CEMOPLAF versus Non-CEMOPLAF
For market identification purposes it is useful to investigate whether there are any differences
between the characteristics of people buying CEMOPLAF products and those buying products
from other sources.
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Table 2 presents a comparison of characteristics of CEMOPLAF product buyers and purchasers
of other products. According to the table, there was no significant difference in education
between the two groups.

Table 2: Profile of All Pharmacy Purchasers by Source of Products Purchased
SOURCE OF PRODUCTS
Characteristics of users

CEMOPLAF (%)

OTHERS (%)

2.4
32.6
45.4
19.5

3.1
30.2
47.1
19.6

Education
None
Primary
Secondary
Superior
Age Group
<15
15 – 24
25 – 34
35 – 44
45 or more
Sex
Female
Male

3.4
23.8
31.4
28.4
13.0

5.2
21.6
25.4
23.2
24.6

63.3
36.7

55.0
45.0

N=

619

8323

Chi-square
P value

No
significance
(3 df).

<0.001
(4 df)

<0.001
(4 df)

There was a significant difference in age between the two groups. About 84 percent of
CEMOPLAF purchasers were 15 to 44 years of age, with just 70.2 percent of non-CEMOPLAF
product purchasers in this age group. The age difference is likely due to CEMOPLAF’s
concentration on selling contraceptives and other products used by women of fertile age.
CEMOPLAF purchasers were significantly more likely than other product buyers to be female,
as is consistent with the reproductive health orientation of the CEMOPLAF product line.
2. Profile of Contraceptive Purchasers – CEMOPLAF versus Non-CEMOPLAF
Contraceptives are the major products sold by CEMOPLAF, and CEMOPLAF contraceptives are
92.5 percent of all contraceptives sold. Table 3 shows the distribution of educational level, age
group, sex, and partner status of CEMOPLAF contraceptive purchasers. These data are
contrasted in the same table with the 26 people who bought other brands of contraceptives.
In terms of educational attainment, those who bought CEMOPLAF contraceptives had an overall
lower level than persons buying other contraceptive brands. Thirty-seven percent of
CEMOPLAF contraceptive purchasers had less than secondary education versus only 19.2
percent of other contraceptive brand buyers. In terms of age, 70.3 percent of CEMOPLAF
contraceptive buyers were in the 25 to 44 year age group. In contrast, 50 percent of other brand
buyers were in that age group. Females were 63 percent of all CEMOPLAF contraceptive
purchasers, and 69.2 percent of non-CEMOPLAF contraceptive buyers.
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Table 3: Profile of Contraceptive Purchasers by Source of Product
Characteristics of users
Education
None
Primary
Secondary
Superior
Total
Age Group
<15
15 – 24
25 – 34
35 – 44
45 or more
Total
Sex
Female
Male
Total
Has partner
Yes
No
Total

SOURCE OF PRODUCTS
CEMOPLAF
OTHERS
%
N
%

N

1.9
35.4
45.8
16.9
100

6
113
146
54
319

19.2
42.3
38.5
100

5
11
10
26

1.6
24.0
37.2
33.1
4.1
100

5
76
118
105
13
317

3.8
23.1
19.2
30.8
23.1
100

1
6
5
8
6
26

62.9
37.1
100

200
118
318

69.2
30.8
100

18
8
26

78.0
22.0
100

245
69
314

72.0
28.0
100

18
7
25

B. Characterization Of CEMOPLAF Products Purchased
1. Types of Products Purchased
Contraceptives account for 44.5 percent of all CEMOPLAF product sales, as shown in Table 4.
Contraceptives are followed in sales volume by antispasmodics (15.4% of all CEMOPLAF
sales), antibacterials/antimicrobials/antivirals (11.2%), cough suppressants (6.3%), laxatives
(4.3%), anti-inflammatory drugs (3.8%), and cold remedies (3.5%). The non-CEMOPLAF
products most frequently purchased were: analgesics (15.5%), antimicrobials/antivirals (14.2%),
and anti-inflammatory drugs (13%). These are drugs that could be more strongly promoted by
CEMOPLAF to capture some of the market going to other brands of those drugs.
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Table 4: Types of Products Purchased in Pharmacies by Source
SOURCE OF PRODUCTS
CEMOPLAF
OTHERS
%
N
%
N
Contraceptives
320
27
44.5
0.3
Antispasmodics
111
305
15.4
2.9
Antibacterials, anti-microbials, antivirals
81
1503
11.2
14.2
Cough suppressants
45
253
6.3
2.4
Laxatives
29
22
4.0
0.2
Pregnancy tests
13
5
1.8
0.05
Anti-inflamatories
27
1371
3.8
13.0
Cold remedies
25
671
3.5
6.4
Vitamins
9
1026
1.3
9.7
Anti-helminths
6
223
0.8
2.1
Anti-mycotics
5
174
0.7
1.6
Analgesics
16
1620
2.2
15.3
Other
32
3365
4.4
31.9
Total
100
719
100
10565
*Classification of medicine products was done by CEMOPLAF medical consultants.
Types of Products*

2. Types of Contraceptives Purchased
A list of specific CEMOPLAF contraceptives purchased in the study pharmacies is shown in
Table 5. Oral contraceptives were by far the most frequently sold type of CEMOPLAF product,
accounting for 52.8 percent of CEMOPLAF contraceptive sales, led by the brands Lo Femenal
(29.7%) and Microgynon (14.1%). OCs were followed by condoms at 29.7 percent, injectables
at 17.5 percent, and barrier methods at 0.3 percent.
Oral contraceptives accounted for one-half of all non-CEMOPLAF contraceptive sales, led by
the brand Triquilar (19.2%). The single most frequently purchased non-CEMOPLAF
contraceptive was Norform vaginal tablets (34.6%). The injectable contraceptive Gynodian
comprised 15.4 percent of the non-CEMOPLAF contraceptive market. No condoms were sold in
the study pharmacies that were non-CEMOPLAF brands.
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Table 5: Types of Contraceptives Purchased in Pharmacies by Source
Type and Brand

SOURCE OF PRODUCTS
CEMOPLAF (%)
OTHER (%)

Oral Contraceptives
Lo Femenal
Microgynon
Nordette
Duofen
Gynera
Exluton
Triquilar
Neogynon
Diane
Climene
Climatrol
Rainobow
Injectables
Topasel
Mesigyna
Depo Provera
Gynodian
Condom
Vaginal Tablets
Conceptrol
Norforms
Total
N=

29.7
14.1
1.6
0.6
0.3
1.2
-

19.2
7.7
7.7
7.7
3.8
3.8

16.6
5.0
0.94
29.7

15.4
-

0.3
100
320

34.6
100
26

3. Types of Pregnancy Tests Purchased
Table 6 shows the types and sources of pregnancy tests purchased. Of 17 pregnancy tests
purchased by study subjects, 13 (76.5%) were CEMOPLAF brands.

Table 6: Types of Pregnancy Tests Purchased in Pharmacies by Source
Brand
Detector
Pecolor PE
Affirm PE
Cliane
Total

SOURCE OF PRODUCTS
CEMOPLAF
OTHERS
%
N
%
7
53.8
6
46.2
50.0
50.0
100
13
100

N
2
2
4
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4. For Whom Product Was Purchased
Table 7 shows that approximately half of all pharmaceutical purchases were made for people
other than the purchaser him/herself, with men purchasing for themselves in 55 percent of the
cases and females for themselves in 50.4 percent. Purchases made for one’s spouse/partner
accounted for 10.4 percent of male purchases and 4.7 percent of female purchases. Twenty
percent of female purchases were made for their own child, while this held true for about 10
percent of men’s purchases. For both men and women, purchases were frequently made for
persons older than the purchaser him/herself, such as a mother/father, aunt/uncle, or grandparent
(13% of purchases).

Table 7: For Whom Product Was Purchased, by Gender of Interviewee
GENDER OF INTERVIEWEE
Male (%)
Female (%)
55.1
50.4
10.4
4.7
9.8
19.5
12.7
13.0
7.8
7.4
2.2
3.4
2.0
1.6
100
100
3970
4969

For whom product was purchased
Self
Spouse or partner
Son/daughter
Another older person
Another person of same age
Another younger person
Other
Total
N=

Table 8 shows that pregnancy tests and non-contraceptive medicines were approximately divided
among purchases for self and for others. Contraceptives, on the other hand, were purchased for
oneself in 81.7 percent of those cases.

Table 8: For Whom Pharmaceutical Product Was Purchased, by Type of Product
For whom product
was purchased
Self
Other
N=

Contraceptives
(%)
81.7
18.3
300

TYPE OF PRODUCT
Pregnancy Test
Medicine
(%)
(%)
46.2
53.8
13

49.3
50.7
306

Total
(%)
65.0
35.0
619

5. Use of Physician Prescription for Pharmaceutical Purchase
The effect of physician prescription on purchase of CEMOPLAF products is shown in Table 9.
On average, 34.6 percent of all CEMOPLAF oral contraceptives and 28.9 percent of injectable
contraceptives were purchased with a prescription. Prescriptions were generally not used for
condom purchases. Among non-contraceptive CEMOPLAF products sold, an average of 26.1
21

percent were purchased with a physician prescription. The large proportion of pharmaceutical
products sold without a prescription is not altogether unusual for the Latin American region.
This information can help CEMOPLAF identify which products are being successfully promoted
through private physicians, and which could be more strongly promoted.

Table 9: Purchase of CEMOPLAF Products with or without Medical Prescription
CEMOPLAF Products
Oral Contraceptives
Lo Femenal
Microgynon
Nordette
Duofen
Gynera
Exluton
Total
Injectables
Topasel
Mesigyna
Depo Provera
Total
Condom
Total
Vaginal Tablets
Conceptrol
Total
Pregnancy Tests
Pecolor PE
Detector

Purchased with
prescription
%

Purchased without
prescription
%

40.0
17.8
50.0
100
34.6

60.0
82.2
50.0
100
100
65.4

90
45
4
2
1
2
144

46.7
40.0
28.9

53.3
60.0
100
71.1

45
15
3
63

1.1

98.9

92

100
100

-

1
1

Total
N

-

100

6

14.3

85.7

7

7.7

92.3

13

16.1
6.9

83.9
93.1

31
72

48.1

51.9

27

Rotopar
Compofen
Clamox
Mobic
Ducolax

100
27.3
87.5
33.3

72.7
12.5
66.7

6
11
8
12

13.0

87.0
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Neogripal
Trigentax
Bacticel
Doxifen
Invigan

9.1
42.9
83.3
100
33
26.1

90.9
57.1
16.7
100
66.7
73.9

11
7
6
1
2
3
220

Total
Other CEMOPLAF Medicine
Bisolvon
Buscapina
Bacterol

Materna
Total
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6. Reasons for Utilization of Study Pharmacies
The data presented in Table 10 compares CEMOPLAF product purchasers with purchasers of
non-CEMOPLAF products based on the reasons for shopping at the pharmacy in which they
were interviewed. Convenience was the major reason for using a particular pharmacy for
purchase, accounting for 28.9 percent and 31.7 percent of the two groups, respectively. From
there, the two groups diverge somewhat in their stated motivations. Seventeen percent of
CEMOPLAF users purchased at that particular pharmacy because they perceived costs were
lower, 14.5 percent because of random chance, 14.1 percent because they received better
treatment there, and 8.1 percent because they had greater confidence in that pharmacy due to a
personal relationship with the owner. Among non-CEMOPLAF product purchasers, aside from
the most important reason of convenience, 15.5 percent shopped at that particular pharmacy due
to random chance, 13.0 percent because costs were lower, 12.0 percent because they had greater
confidence, and 11.1 percent because they received better treatment there.

Table 10: Reasons Given for Using Pharmacy, Comparing Purchasers of CEMOPLAF
and Non-CEMOPLAF Products
Reasons for using pharmacy
Convenience
Lower costs
Better treatment
Random chance
More confidence (e.g. in quality)
Habit or custom
Has everything one could need
Needed a product
Only pharmacy available
Has good products
Hours of operation
First time client
Only one with the desired product
Other
Total
N=

SOURCE OF PRODUCTS
CEMOPLAF (%)
OTHERS (%)
31.7
28.9
13.0
17.1
11.1
14.1
15.5
14.5
12.0
8.1
6.8
7.3
5.4
3.4
2.0
3.2
1.0
1.6
0.7
1.0
0.3
0.6
0.2
0.2
0.4
0.3
100
100
619
8323

The reasons for attending a particular pharmacy could vary by how close to the pharmacy they
live or work. In all, 63.5 percent of persons interviewed lived or worked near the pharmacy in
which they were interviewed, while 36.5 percent came from outside the area. Specific reasons
why the pharmacy was used, comparing those who lived or worked nearby with those who did
not, are shown on Table 11. For 42.2 percent of those living or working nearby, pharmacy use
was due to convenience for the buyer. For 35.4 percent of those coming from outside the area,
use of the pharmacy was due to random chance. Seeking lower costs was the reason for 14.9
percent of people coming from outside the areas versus 11.9 percent of those who live nearby,
suggesting that some people were specifically drawn in for economic reasons. People from
outside the area were also attracted by the good treatment and the availability of most products.
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Other reasons were distributed more or less randomly by place of residence. These data suggest
that the pharmacies that sell CEMOPLAF products are in desirable locations that are highly
accessible to both local residents and outsiders.

Table 11: Reasons for Use, Comparing Purchasers Living or Working near Pharmacy with
Those Who Don’t
LIVE OR WORK NEAR THE
PHARMACY
YES(%)
NO (%)
13.0
42.2
35.4
4.0
14.9
11.9
10.8
11.3
8.4
13.7
5.6
7.6
6.1
4.7
0.8
0.6
1.4
0.9
1.9
2.2
0.7
0.2
0.4
0.3
0.5
0.1
0.2
0.2
100
100
5679
3263

Reasons for using pharmacy
Convenience
Random chance
Lower costs
Better treatment
More confidence (e.g. in quality)
Habit or custom
Has everything one could need
Has good products
Only pharmacy available
Needed a product
Only one with the desired product
Hours of operation
First time client
Other
Total
N=

Table 12: Reasons Given for Using Pharmacy, by City
Reasons for using pharmacy
Convenience
Random chance
Lower costs
Better treatment
More confidence (e.g. in quality)
Habit or custom
Has everything one could need
Has good products
Only pharmacy available
Needed a product
Only one with desired product
Hours of operation
First time client
Other
Total
N=

CITY IN ECUADOR
Quito (%)

Guayaquil (%)

Sto. Domingo (%)

Riobamba (%)

Ambato (%)

36.5
10.9
8.0
7.5
10.0
12.4
5.3
0.8
1.7
5.2
0.8
0.6
0.3
100
2993

31.4
22.0
15.0
10.4
10.9
1.2
6.9
0.3
0.2
0.3
0.4
0.1
0.7
0.2
100
2675

19.3
9.5
23.1
23.4
13.9
4.2
4.0
0.5
0.7
1.0
0.1
0.2
100
1746

39.2
18.4
8.1
6.3
7.0
10.5
5.2
1.7
2.1
0.3
1.0
0.3
100
942

31.2
22.4
6.5
3.8
25.8
6.3
0.9
1.2
1.2
0.5
0.3
100
586

24

For all pharmacy users, the reasons given as most important for having utilized that pharmacy
had some interesting variations by city of residence that reflect differences in consumer culture.
Table 12 shows that convenience was the major reason for using a pharmacy in all cities except
Santo Domingo, a tropical inland city at sea-level, where lower costs and better treatment were
the most important reasons. In addition to Santo Domingans, Quiteños were less likely to use a
pharmacy due to random chance as compared to other cities. Rather, Quiteños, as well as
Riobambans, had more of a propensity than people in other cities to use a pharmacy from habit
or custom. Ambato, a smaller-sized traditional town in the mountains, was the only one in which
greater confidence in the pharmacy or its owners was one of the main reasons given for using the
pharmacy in which they were interviewed.
7. Products Sought but Not Found
A total of 167 (1.9%) of the 8,942 study subjects did not find a product for which they had gone
to find at the pharmacy. The list of products sought but not found at the pharmacies are listed by
type in Table 13, classified by whether or not the pharmacy client had also bought a
CEMOPLAF product. The products most frequently not found were
antibacterial/antimicrobial/antiviral medicines such as antibiotics, analgesics, anti-inflammatory
medicines, vitamins, and cold remedies. These data suggest the types of products that
CEMOPLAF could use to expand the range of their market, especially since these five types of
products coincide with the non-CEMOPLAF products that were most frequently purchased, as
was shown on Table 4.

Table 13: Pharmaceutical Products Sought but not Found in Pharmacies by Study
Population
Product not found
Antibacterials, anti-microbials, antivirals
Analgesics
Anti-inflamatories
Vitamins
Cold remedies
Antidepressants
Anti-diabetics
Other
Total
N=

SOURCE OF OTHER PURCHASES
CEMOPLAF (%)
OTHERS (%)
25.0 (1)
10.4
7.4
7.4
7.4
4.9
3.7
3.7
75.0 (3)
55.1
100
100
4
163

IV. Discussion and Recommendations
In 1999, the CEMOPLAF project sold 21 contraceptive products and 22 other pharmaceutical
products (some in various presentations such as capsules, syrups, and child and adult doses).
Some of the products were purchased by CEMOPLAF from pharmaceutical companies
(pregnancy tests, prescription drugs, etc.) and others were USAID donations (Lo-Femenal,
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DMPA, IUDs, condoms). The highest selling products were pills (300,000 per year), condoms
(800,000 per year), injectable contraceptives (75,000 doses annually), and home pregnancy tests
(50,000 tests per year). The list of CEMOPLAF products and sales figures for 1999 is found in
the appendices.
The amounts of CEMOPLAF products reported as purchased in the current market survey are
roughly proportional to the 1999 sales figures. This helps to confirm the validity of the random
selection procedures used to draw the sample of pharmacies and pharmacy clientele.
A summary of market assessment findings and recommendations follow:
1. Data showing differences in socioeconomic characteristics of pharmacy clientele between
the five study cities in educational attainment, age, gender, and partner status reflect the
general socioeconomic and cultural environment of each city. It is a reminder that
CEMOPLAF sales promotion strategies should take different approaches in different
cities according to the socioeconomic profile of the local users.
2. The study showed few differences in socioeconomic characteristics between pharmacy
clients who purchased CEMOPLAF products versus purchasers of non-CEMOPLAF
products, except for those related to higher concentration of contraceptive purchasers
among CEMOPLAF buyers. That is, CEMOPLAF purchasers were more frequently
women of fertile age. However, when only contraceptive purchasers are considered, the
study results suggest that, compared to non-CEMOPLAF contraceptive purchasers,
CEMOPLAF buyers are generally from a lower level of educational attainment, and that
a relatively important reason for them to purchase at the pharmacy was to get a lower
price. Convenience and lower cost were the two major reasons why CEMOPLAF
product buyers shopped at the pharmacy where they made a purchase. These findings
suggest that CEMOPLAF should continue to use promotional strategies that target lower
socioeconomic populations. At the same time, it is possible that a higher socioeconomic
class of buyers could be targeted by special promotional efforts in order to further expand
the market.
3. The non-CEMOPLAF products most frequently purchased were analgesics,
antibacterials/antimicrobials/antivirals, anti-inflammatory drugs, vitamins, and cold
remedies. These were also, not so coincidently, the items most frequently sought but not
found. CEMOPLAF already sells selected products in these categories. Since there is a
large demand for them, CEMOPLAF could move more strongly into these products to
capture more of their market.
4. Information on whether a medicine was purchased with a physician’s prescription is
useful for monitoring how successful the CEMOPLAF program is in promoting specific
pharmaceutical brands through private physicians.
5. The large proportion of persons coming from outside the immediate neighborhood of the
study pharmacies (36.5%) suggests that an expansion of pharmacies to new
neighborhoods would capture additional clients who would be attracted to CEMOPLAF
products by lower prices.
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A. Recommendations for future market profile studies
As a final conclusion of the present market assessment of the CEMOPLAF customer profile, we
can say that the same methods and variables used for this study should definitely be utilized for
on-going periodic monitoring of the CEMOPLAF social marketing program. The current study
will serve as a baseline, and future efforts will show how customers are responding to marketing
and pricing strategies employed by CEMOPLAF.
The following are suggestions for future market profile studies:
1. The questionnaire should include information on amount (i.e. number of doses) and price
paid for each specific product purchased.
2. It is suggested that the questionnaire used for this study be redesigned to ensure that
information is captured about each medicine purchased by each interviewee. For each
medicine mentioned, questions should be asked about for whom is the medicine and if a
prescription was used for its purchased.
3. The question regarding for whom the product is purchased could use just three categories
of possible responses: self, spouse or partner, or other. This would shorten the time
needed to fill out the questionnaire, and would especially simplify the data input and data
analysis.
4. Incentives or gifts should not be given to pharmacy survey respondents due to the risk of
altering the normal purchasing habits of the population.
5. The sample size should be increased if possible to allow a larger number of CEMOPLAF
product buyers to fall into the sample so that analyses of their characteristics would have
more statistical power, and more disaggregated analyses could be carried out.
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STUDY III: QUALITY OF CARE ISSUES IN DELIVERY OF
INJECTABLE AND ORAL CONTRACEPTIVES AND A
PREGNANCY TEST IN ECUADOREAN PHARMACIES
Authors: Federico R. León, James R. Foreit, Rosa Monge, Ana María Buller, Teresa de Vargas,
Ernesto Pinto, & María del Rosario Naranjo

I. Introduction
Reproductive health programs face a major challenge: to provide a greater variety of products
and services to a rapidly increasing number of users. CEMOPLAF is a non-governmental
organization (NGO) that operates a variety of reproductive health programs throughout Ecuador,
including 21 reproductive health clinical centers and a social marketing program. Today, social
marketing is the largest producer of CEMOPLAF’s revenue, accounting for approximately 36
percent of gross income (approximately $67,000 per month). The program sells contraceptive
and reproductive health products to pharmacies, physicians, and other distributors and nontraditional outlets including liquor stores, hotels, motels and brothels. The program sells 34
purchased products (pregnancy tests, prescription drugs, etc.) and USAID donated products (LoFemenal, DMPA, IUDs, condoms). In terms of sales, the most important are pills (234,000
cycles per year), condoms (800,000 packages of three per year), injectable contraceptives
(100,000 doses per year), and home pregnancy tests (40,000 tests per year).
CEMOPLAF has conducted evaluation and operations research (OR) to improve its social
marketing program as an effective channel for delivering family planning and reproductive
health services (e.g., Bratt et al., 1994, 1995, 1998). This research has been concerned with the
economic aspects of the program. Another aspect of the program in need of research is the
quality of the client-pharmacist interaction. CEMOPLAF is concerned that social marketing
clients purchasing hormonal methods receive adequate information and management of methodrelated side effects. CEMOPLAF clinical service norms require that users of hormonal methods
receive counseling at acceptance and follow up, but no official policy governs quality of
information that pharmacists should give to clients.
This study was designed to obtain inputs for the design of interventions to enhance pharmacist
information-giving behavior. The study objective was to collect observations on the clientpharmacist interaction during the provision of oral and injectable contraceptives and pregnancy
tests to identify strengths and weaknesses.

II. Methods
CEMOPLAF medical staff decided the minimum information that pharmacists should be able to
provide customers using DMPA (Depo-Provera), combined oral contraceptives, and a pregnancy
test. On this basis, research staff constructed three Service Tests, one per product, to assess the
extent to which pharmacists give information to customers. A Service Test consists of a set of
instructions to perform as a simulated client (customer profile) and register behavioral
observations on a checklist. The customer profile contains a set of instructions concerning what
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the simulated client must say or ask the pharmacist. The checklist includes expected pharmacist
behaviors whose presence must be verified by the simulated customer. For contraceptives, these
included talking about contraindications, giving instructions for correct use, and side effects of
the method.
Female physicians were selected to conduct the Service Tests. In the case of the injectable
contraceptive, the customer profile referred to a healthy 30 year-old woman who had a 1.5 yearold child, was presently menstruating, was a user of the calendar rhythm method, and wanted to
start using DMPA (Depo-Provera). She was trained to visit pharmacies as a simulated client and
ask, “Can you please give me an injectable contraceptive?” If the pharmacist offered several
brands, she was expected to ask, “Which one would you recommend?” and choose one (DepoProvera, unless it was not offered). If the pharmacist did not spontaneously provide usage
instructions, she would ask, “How should I use it?” and then, “What should I do if I forget to
apply it in the expected date?” if the pharmacist did not provide this instruction. The simulated
client was trained to use the checklist and register her observations as soon as she left the
pharmacy.
The client profile for combined oral contraceptives referred to a healthy woman between 25 and
30 years who had a 1.5 year-old child, was presently menstruating, was a user of the calendar
rhythm method, and wanted to start taking pills. She was trained to visit pharmacies as a
simulated client and ask, “Can you please give me a package of contraceptive pills?” If the
pharmacist offered several brands, she was trained to ask, “Which one would you recommend?”
and choose one. If the pharmacist did not spontaneously provide usage instructions, she would
ask, “How should I take them?” and then, “What should I do if I forget to take them every day?”
if the pharmacist did not provide this instruction.
Finally, the client profile for the pregnancy test referred to a young woman (17 to 30 years old)
that suspected she was pregnant and wanted to rule out this possibility using a pregnancy test.
She was trained to visit pharmacies as a simulated client and ask, “Can you please give me a
pregnancy test?” If the pharmacist offered several brands, she was expected to ask, “Which one
would you recommend?” and choose one. If the pharmacist did not spontaneously provide usage
instructions, she would ask, “How should I use it?” As in the two previous cases, the simulated
client was trained to use the checklist and register her observations as soon as she left the
pharmacy.
The population of the study included all the pharmacies that were clients of CEMOPLAF in five
Ecuadorean cities. Stratified random sampling was used to choose 15 pharmacies in Guayaquil
and 15 in Quito (five each from northern, central, and southern city areas). In Ambato and
Riobamba, 5 pharmacies were randomly chosen in each city. Ten were chosen in Santo
Domingo. One simulated client visited the 50 pharmacies requesting DMPA, another requesting
pills, and the third requesting a pregnancy test.
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III. RESULTS
A. Injectable
Injectable contraceptives were available in the 50 pharmacies. Figure 1 describes the observed
flow of client-pharmacist interactions. Of the 50 pharmacists involved, 41 offered the simulated
client the option to choose the brand. Only 9 pharmacists offered just one brand to the client.
(The study did not ascertain whether this was due to the lack of alternative brands in stock or
preferences of the pharmacists.) Regardless of number of brands offered, 28 pharmacists
spontaneously offered information about the injectable contraceptive(s) and 22 failed to do so.
When the simulated client asked for information she received it in all cases.
Table 1 presents specific information per item of the checklist taking into account the phase of
the client-pharmacist interaction. Phase A mainly encompasses the pharmacist’s spontaneous
initiatives; the only request from the client in this phase concerned the guidance to choose one of
the brands. In Phase B, the pharmacist was responding to the client’s specific request for usage
instructions. In Phase C, the pharmacist responded to the client’s request for advice concerning
what to do if she forgot to apply the injection in the due date.
About one-third of the total number of pharmacists spontaneously stated prices and asked the
client whether she was a new user. These figures increased to almost one-half in the second
phase of the client-pharmacist interaction. At the end of the third phase, information concerning
prices was given to the client in more than three fourths of the cases. The only question asked to
screen the client for contraindications was whether she was menstruating (to rule out pregnancy).
Twenty-two pharmacists failed to ask this question.
About one-third of the pharmacists spontaneously informed the client that the injection is applied
the first time when the woman is menstruating and then every three months (Phase A). When the
client asked for usage instructions, 90 percent or more of the pharmacists referred to the presence
of menstruation for the first injection and the 3-month interval between injections. Only when
the client asked specifically what to do if she forgot an injection did some of the pharmacists
address the issue and the ensuing risk of pregnancy. Pharmacists did not talk about the inserts
within the product packages. Information given to the client about side effects was practically
nonexistent.
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Figure 1. Injectable: Distribution of Cases in the Client – Pharmacist Interaction Dynamics
USER: Could you give me please a contraceptive injectable? (50)
9
PHARMACIST: Offers
an injection
gives
information
5

gives no
information
4

12
PHARMACIST: Offers
several brands
gives
information

29
PHARMACIST: What
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gives no
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5

0
PHARMACIST: There
are no injections

USER: Which one do
you recommend?

7

END

USER: Which one
do you recommend?

offers one
brand
7

offers
injections
22

offers other
methods

0

gives
gives no
gives
gives no
information information information information
5
2
13
9

A

USER: Chooses one: _______

B
USER: How shall I use it?
USER: What should I do if the injection is not administered in the expected date?

C

USER: Buys the injection or declines buying it
END
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Table 1. Injectable: Information given/asked by pharmacist in each phase of
interaction with client, n=50
Items
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Price
Is this your first time?
Contraindications
Check it with your physician
Pregnancy
Are you menstruating?
Non-menstrual vaginal bleeding
Hard formations in the breast or breast cancer
Usage Instructions:
Injection administered every three months
First injection administered during menstruation
Forgetfulness
Risk of pregnancy
Reading instructions
Side Effects
Menstruation may be irregular or spotting may be observed
There may be lack of menstruation
Temporary infertility after discontinuation

A

Phase
B

C

16
20

4
9

22
0

2
1
14
1
0

0
0
14
2
0

0
0
0
0
0

19
12
1
1
0

27
33
4
3
0

0
0
12
24
0

3
0
0

1
0
0

0
0
0

B. Pills
Pills were available in the 49 pharmacies of the sample (there was 1 missing case). Figure 2
describes the observed flow of client-pharmacist interactions. Of the 49 pharmacists involved, 40
offered the simulated client the option to choose the brand. Only 9 pharmacists offered just one
brand to the client, and this study did not ascertain whether this was due to the lack of alternative
brands in stock or preferences of the pharmacists. Regardless of number of brands offered, 16
pharmacists spontaneously offered information about the pills and 31 failed to do so. When the
simulated client asked for information, she received it in all cases. There were also two
pharmacists that offered other methods.
Table 2 presents specific information per item of the checklist taking into account the phase of
the client-pharmacist interaction. Phase A mainly encompasses the pharmacist’s spontaneous
initiatives; the only request from the client in this phase concerned the guidance to choose one of
the brands. In Phase B, the pharmacist was responding to the client’s specific request for usage
instructions. In Phase C, the pharmacist responded to the client’s request for advice concerning
what to do if she forgets to take the pill everyday.
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Figure 2 Pill: Distribution of Cases in the Client – Pharmacist Interaction Dynamics
1
Missing cases: 1
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Table 2. Pills: Information given/asked by pharmacist in each phase of interaction
with client,
n=49
Items
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Price
Is this your first time?
Contraindications
Check it with your physician
Are you menstruating?
Pregnancy
Breastfeeding
Non-menstrual vaginal bleeding
Hard formations in the breast or breast cancer
Cardiovascular diseases
Liver diseases
Usage Instructions:
Every day
Use of package
Forgetfulness
Risk of pregnancy
Restart
Reading instructions
Side Effects
Headache
Sickness
Nervousness

A

Phase
B

C

24
12

3
9

21
0

2
8
0
0
0
1
1
1

1
7
1
1
0
0
0
1

0
0
0
0
0
0
0
0

6
4
3
0
1
0

39
25
3
2
1
1

1
2
25
21
5
0

0
0
0

1
0
0

0
0
0

As shown by Table 2, half of all pharmacists stated prices and a quarter asked the client whether
she was a new user, both in the first phase. Information about contraindications or usage
instructions was very low in this phase; the most frequently reported items (“are you
menstruating?” and “pills must be taken every day”) were mentioned by only 15 percent of
pharmacists.
When the client asked for usage instructions (Phase B), 80 percent of the pharmacists said that
pills must be taken every day and about 50 percent referred to the correct use of the package.
Only when the client asked specifically what to do if she forgot to take a pill, did some of the
pharmacists address the issue and the ensuing risk of pregnancy. Pharmacists did not talk about
restarting pills or about inserts within the product package. Information given to the client about
side effects was practically nonexistent in the three phases.
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C. Pregnancy Test
There were three missing cases. Pregnancy tests were sold in 46 pharmacies. Figure 3 shows
the flow of client-pharmacist interactions. Of the 46 pharmacies, 29 offered the simulated client
the option to choose the pregnancy test brand while 17 pharmacists offered one brand to the
client. (The study did not ascertain whether this was due to the lack of alternative brands in stock
or preferences of the pharmacists.) Regardless of number of brands offered, it can be observed
that the great majority of pharmacists (45) did not spontaneously offer information about the
pregnancy test. When the simulated client asked for information, she received it in all cases.
In this Service Test, Phases A and C mainly encompasses the pharmacist’s spontaneous
initiatives, while Phase B encompasses the pharmacist’s answers to the client’s question about
usage instructions (see Figure 3).
Most pharmacists stated prices in the first phase and about 1/3 in the second phase. Only two
pharmacists gave instructions spontaneously (Phase A), whereas half of the cases gave
instructions or told the simulated client to read them in the second phase, that is, after the
simulated client specifically asked how to use the product (Table 3). Questions about the
probable date the pregnancy, or the suggestion to check with a physician were nonexistent.
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Figure 3. Distribution of Cases in the Client – Pharmacist Interaction Dynamics
3
Missing cases: 1
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Table 3. Pregnancy Test: Information given/asked by pharmacist in each phase of
interaction with client, n=46
Items

A

Phase
B

C

1

Price

27

17

3

2
3

How long has your menstrual period been missing
Check it with your physician
Usage Instructions (depending on the test)
Gives instructions
Reads instructions

0
0

0
0

0
0

2
0

24
24

0
0

4
5

IV. Discussion
This study revealed that pharmacists behave very much like clinical providers of family planning
methods: they tend to formulate questions concerning the menstrual status of the client and give
her usage instructions but little or no information about side effects and contraindications (León
et al., 1999).
On the other hand, the study showed that the pharmacist’s asking standard questions and giving
usage instructions are increased when the client formulates specific questions. This suggests an
intervention to enhance provider’s information-giving behavior: stimulating the client to
formulate questions, which can be done by placing posters with appropriate messages within the
pharmacies.
The same intervention could be used to change pharmacist information-giving behavior
concerning contraindications and side effects. In this case, the posters would have to specifically
tell the client to ask for contraindications and side effects.
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CONFERENCE: SUSTAINABILITY AND SOCIAL MISSION:
SHARING LESSONS FROM RESEARCH AND PRACTICE
Author: Kristina Lantis

I. Introduction
The conference, Sustainability and Social Mission: Sharing Lessons from Research and Practice,
was held May 16 – 18, 2001 in Quito, Ecuador. Over 80 attendees representing more than 40
organizations and 12 countries met to discuss how to improve financial sustainability through the
use of business practices while continuing to fulfill their social mission of serving the poor. The
conference was sponsored by CEMOPLAF of Quito, Ecuador, and by two United States Agency
for International Development (USAID) funded projects, Frontiers in Reproductive Health and
Commercial Market Strategies (CMS).

II. Attendees
More than 80 individuals registered to attend the conference. They represented over 40 family
planning organizations, research organizations, pharmaceutical companies, and donors. A
complete list of registrants can be found in the appendix.

III. Conference Objectives
The conference objectives were to:
•

Share sustainability research and lessons learned;

•

Share experiences of NGOs that have attempted to improve the sustainability of programs
while maintaining their commitment to social mission; and

•

Provide NGOs and companies that market reproductive health products the opportunity
to explore the possibility of commercial agreements.

IV. Agenda
The conference consisted of three full days of panel presentations, question and answer sessions,
roundtable sessions and open discussions. Presentations were given in both Spanish and English
with simultaneous translation. A copy of the agenda can be found in the appendix.

A. Day One
The conference began with a welcome and statement of objectives from representatives of the
three sponsoring organizations: Teresa de Vargas, CEMOPLAF; Alvaro Monroy, CMS; and
Ricardo Vernon, FRONTIERS.
38

The first panel, Sustainability vs. Social Mission: What do programs need to do?, discussed the
definitions of both social mission and sustainability, their compatibility and the challenges NGOs
and the commercial sector will face with regard to sustainability and social mission.
Following a discussion of Panel 1, four discussion groups were formed for participants to discuss
donor expectations, barriers to commercial growth, definition of social mission and private
sources of funding.
The second panel discussed research findings from Ecuador, Guatemala, Honduras, and El
Salvador on the impact of sustainability activities on program utilization and client profile. The
panel was followed by a 45-minute open discussion of agency experiences with the impact of
price increases on utilization.

B. Day Two
Two panels took place in the morning of the second day. The first discussed various market
research tools including market research surveys, willingness to pay surveys, psycho-behavioral
market segmentation and focus groups and other qualitative techniques. The second panel,
Calculating and Using Cost Information, discussed calculating costs, price setting, profitability
analysis and cross-subsidies. Both panels were followed by half-hour discussion sessions.
Panelists in the afternoon discussed marketing strategies for reproductive health services such as:
in-reach and missed opportunities, quality, diversification, the addition of commercial marketing
and selling to the commercial sector.
Representatives from CMS, FRONTIERS and The Futures Group International (TFGI) provided
participants with assistance in obtaining research tools and discussed opportunities for research
collaboration at a round table session.

C. Day Three
The final day of the conference began with a presentation on alternative financing mechanisms.
Representatives from various commercial sector companies, including CPR, Drogueria Inti,
General Electric Health Systems and Schering, discussed “What can the commercial sector offer
NGOs to make them more sustainable?” in Panel 6.
The final two round tables of the conference discussed the experiences of Latin American
agencies with products and services, both profitable and non-profitable.
The conference closed with comments and conclusions from Alvaro Monroy, CMS and Teresa
de Vargas, CEMOPLAF.
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V. Sustainability Snapshot
Organizations attending the conference were asked to complete a form concerning their budgetstructure (percent donor vs. percent self-generated) and future of donor funding.
•

11/20 organizations indicated they were more than 50 percent self-sustainable (more than
50 percent of their budget was self-generated).

•

Of those >50 percent self-sustainable organizations, 2/11 said their donor funding would
remain stable and 9/11 indicated that their donor funding would be decreasing.

•

9/20 organizations were less than 50 percent self-sustainable (more than 50 percent of
their budget came from donor funds), of these organizations 5 predicted decreasing donor
funding, 3 predicted their donor funding would remain stable and one predicted its donor
funding would increase.

•

19/20 organizations indicated their donor funding would either remain stable (5) or would
decrease (14). The one organization that indicated its donor funding would increase is
also 0 percent self-sustainable.

•

When funding structure information was combined for all 20 organizations and averaged,
45 percent of the budget was donor funded and 55 percent was self-generated.

•

2/20 organizations indicated that 100 percent of their budget came from donor funds. If
these two organizations are not included, the average budget structure for the remaining
18 is: 39 percent donor funded and 61 percent self-generated.

VI. Conference Evaluation
Results of the conference evaluation are available in the appendix. More than eighty percent of
the participants felt the conference met its objectives and found the ideas useful and practical.
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APPENDICES
Appendix 1 – Allocation Decisions and Other Assumptions
1. Allocation of Joint Expenses in the Quito Region
Staff Meetings – if the expense was less than S/. 300,000, it was allocated to the Quito sales
agents; otherwise it was allocated to all sales agents.
Courses and Seminars, Promotional Material, Promotion Activities – these expenses were
allocated equally to all sales agents.
Travel and Per diem – these expenses were allocated equally to non-Quito sales agents.
Vehicle Maintenance - these expenses were allocated equally to Quito sales agents.
2. Assumptions underlying Capital Costs
We assumed that each sales agent had access to a computer for record-keeping (invoices,
accounts receivable and payable, etc.), and a basic suite of furniture including a desk, a chair and
a filing cabinet. The SM program also owns a vehicle that is used exclusively in the Quito
region.
The table below presents information used to calculate annualized cost for capital items.

Item
Computer/printer
Office Furniture
Vehicle – Vitara

Purchase Price
1,000
200
11,063

Useful Life
5 years
10 years
10 years

Discount Rate
10%
10%
10%

3. Calculation of Equivalent Rent
An estimate of average rental cost per square meter was needed to compute a monthly
“equivalent rent” for the clinics that CEMOPLAF owns. This estimate was generated using the
data in the following table.

Clinic
Tulcan
Ibarra
Quininde
Quito – COP
Average

Monthly Rent (S/.)
1,000,000
900,000
530,000
1,200,000

Clinic Area (M2)
120
200
130
147

Cost per M2
8,333
4,500
4,077
8,163
6,268
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Appendix 2
CEMOPLAF Social Marketing Program Sales During 1999
Prepared by Dr. Mónica C. De Sánchez
PRODUCT

TOTAL
NUMBER

%

IUD's
Tcu 380 A ( units)
Spirals

64746
1

9.96
0.00

ORAL
CONTRACEPTIVES
Marvelon (dose)
Microgynon (box x 3)
Microgynon CD ( box x 3)
Lo Femenal (dose)
Exluton (dose)
Nordette (dose)
Trinordiol (dose)
Minulet (dose)
Gynera (dose)
Gynera CD
Mercilon
Femiane
Harmonet

2807
19161
19499
226568
13018
3454
1591
6057
3906
3034
1717
969
426

0.43
2.95
3.00
34.85
2.00
0.53
0.24
0.93
0.60
0.47
0.26
0.15
0.07

INJECTABLES
Depo provera
Mesigyna
Topasel

3787
28234
43113

0.58
4.34
6.63

37417
23282

5.76
3.58
0.00

13263
14896
3938
165
17783
3823
2042
2005

2.04
2.29
0.61
0.03
2.74
0.59
0.31
0.31

BARRIER
Panther (units)
Protektor (box x 3)
Conceptrol (units)
OTHER PRODUCTS
Detector x 25
Detector x 10
Detector Gold
Pregcolor
Pregcolor Premium
Clamox óvulos
Clámox cream
Funzal

PRODUCT
OTHER PRODUCTS cont.
Bacterol 20 capsules
Bacterol forte x 10 capsules
Bacterol susp.
Doxifen cream
Doxifen óvulos
Doxifen Dual
Bacticel Simple
Bacticel Forte
Bacticel Susp
Invigan
Compofen
Mobic 7.5
Mobic 15
Mobic syringes
Bisolvon
Buscapina simple
Buscapina (tablets)
Buscapina (syringe)
Buscapina plus (capsules)
Kiddi
Pharmaton
Pharmaton complex
Cutamycon cream
Cutamycon Vag. Tab.
Rotopar tab.
Rotopar susp.
Trigentax cream
Tinidameb
Premarin 0.625
Premarin cream
Materna
Dulcolax
Neogripal x 12
Neogripal x 60
Neogripal syrup
Neogripal drops
TOTAL

TOTAL
NUMBER

%

1588
3724
3500
2590

0.24
0.57
0.54
0.40

2822
299
88
149
189
1118
2886
1458
998
760
9304
1132
6918
5883
4586
3219
2403
2996
1263
493
3766
3607
8260
897
1316
549
5140
1853
868
270
1069
1437
650100

0.43
0.05
0.01
0.02
0.03
0.17
0.44
0.22
0.15
0.12
1.43
0.17
1.06
0.90
0.71
0.50
0.37
0.46
0.19
0.08
0.58
0.55
1.27
0.14
0.20
0.08
0.79
0.29
0.13
0.04
0.16
0.22
100.00
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Appendix 3
CONFERENCE AGENDA: SUSTAINABILITY AND SOCIAL MISSION
Day 1 Agenda: Wednesday, May 16, 2001
8:00 a.m. – 9:00 a.m.
Registration
9:00 a.m. – 9:30 a.m.

Welcome and
Conference Objectives

Teresa de Vargas, CEMOPLAF
Alvaro Monroy, CMS
Ricardo Vernon, FRONTIERS

9:30 a.m. – 10:30 a.m.

Panel 1: Sustainability vs. Social
Mission: What Do Programs Need
to Do?

Moderator: Ney Costa,
BEMFAM

9:30 – 9:45

Definition of sustainability

Alvaro Monroy, CMS

9:45 – 10:00

Are sustainability and social
mission compatible?

Guy Stalworthy, PSI

10:00 – 10:15

Private sector social mission

Santiago Cordova, CELSAM

10:15 – 10:30

NGO and commercial sector
challenges

Karen Foreit, TFGI

10:30 a.m. – 11:00 a.m.

Discussion

11:00 a.m. – 11:15 a.m.

Coffee Break

11:15 a.m. – 12:15 p.m.

Discussion Groups

Moderators:

How much do we expect from
donors and how much must we
raise in non-donor funds to
survive?

Enrique Suárez, FEMAP

Barriers to commercial sector
growth.

José Luis Corral, CELSAM

How do LAC NGOs define social
mission?

Catalina Uribe, PROFAMILIACO

Private donors and foundations as
a source of funding.

Maricela Durá, MEXFAM
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12:15 p.m. – 1:15 p.m.

Discussion Group Presentations

1:15 p.m. – 2:30 p.m.

Lunch

2:30 p.m. – 3:15 p.m.

Panel 2: Research Findings on the
Impact of Sustainability Activities
on Program Utilization and Client
Profile.

Moderator: Karen Foreit, TFGI

2:30 – 2:45

Socio-economic profiles of NGO
clients in Ecuador, Guatemala,
Honduras and El Salvador.

John Bratt, FHI

2:45 – 3:00

Impact of price increases on client
profiles.

Zonia Aguilar, APROFAM

Impact of sustainability activities
on demand for services and client
profile in CEMOPLAF

Ernesto Pinto, CEMOPLAF

Open Floor Discussion of Agency
Experiences with the Impact of
Price Increases on Utilization

Moderator: Teresa de Vargas,
CEMOPLAF

3:00 – 3:15
3:15 p.m. – 4:00 p.m.

Day 2 Agenda: Thursday, May 17, 2001
Panel 3: Market Research Tools
9:00 a.m. – 10:00 a.m.

Moderator: Jim Foreit,
FRONTIERS

Moderator: John Bratt, FHI

9:00 – 9:15

Market research survey

José Alvarez, CHSP

9:15 – 9:30

Willingness to Pay (WTP) surveys

Jim Foreit, FRONTIERS

9:30 – 9:45

Psycho-behavioral segmentation

Ratha Loganathan, CMS

9:45 – 10:00

Focus groups and other qualitative
techniques

Martha Mérida, PROSALUD.

10:00 a.m. – 10:30 a.m.

Discussion

10:30 a.m. – 10:45 a.m.

Coffee Break

10:45 a.m. – 11:45 a.m.

Panel 4: Calculating and Using
Cost Information

Moderator: Ney Costa,
BEMFAM

44

10:45 – 11:00

Calculating Costs

Jésus Servin, FEMAP

11:00 – 11:15

Price setting using cost and other
criteria.

Catalina Uribe, PROFAMILIAColumbia

11:15 – 11:30

Profitability analysis of
CEMOPLAF marketing program

Rosario Naranjo, CEMOPLAF

11:30 – 11:45

When do cross-subsidies work?

Julia Walsh, BIG.

11:45 a.m. – 12:15 p.m.

Discussion

12:15 p.m. – 1:30 p.m.

Lunch

1:30 p.m. – 2:45 p.m.

Panel 5: Marketing Strategies for
Reproductive Health Services

Moderator: Carlos Morlacchi,
ASHONPLAFA

1:30 – 1:45

In-reach and missed opportunities
to provide more services.

Ricardo Vernon, FRONTIERS

1:45 – 2:00

Quality as a marketing strategy.

Miriam Becerra/Agustín Cuesta,
APROFE

2:00 – 2:15

Diversification beyond
reproductive health

Brian Mitchell, BIG

2:15 – 2:30

Adding commercial marketing to
NGO activities.

Ney Costa, BEMFAM

2:30 – 2:45

Selling to the commercial sector.

Magali Caram, PROFAMILIADominican Republic.

2:45 p.m. – 3:15 p.m.

Discussion

3:15 p.m. – 4:15 p.m.

Round Tables: Getting Technical
Assistance for Research.

José Alvarez, CHSP
Ratha Loganathan, CMS

Representatives of CMS,
FRONTIERS and TFGI will
provide help to participants in
obtaining research tools and will
discuss possibilities for research
collaboration with donors and
service delivery agencies.

Jim Foreit/Ricardo Vernon,
FRONTIERS
John Bratt, FHI
Karen Foreit, TFGI
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Day 3 Agenda: Friday, May 18, 2001
8:45 a.m. – 9:15 a.m.
Alternative Financing Mechanisms Carlos Carrazana, Summa
Foundation
9:15 a.m. – 9:45 a.m.

Discussion

9:45 a.m. – 12:15 p.m.

Panel 6: What Can the
Commercial Sector Offer NGOs to
Make Them More Sustainable?

9:45 – 10:15

CPR

Michael Kesserling

10:15 – 10:45

Drogueria Inti

Cristian Schelling

10:45 – 11:15

General Electric Health Systems

Fernando Antúnes

11:15 – 11:45

Hindustani Latex

Alan Forney and Ayappan M

11:45 – 12:15

Schering

Marco Egas

Round Table: Profitable and Nonprofitable Products: The
Experiences of LAC Agencies

Moderator: Carlos Morlacchi,
ASHONPLAFA

ADS
BEMFAM
CEMOPLAF
MEXFAM

Jorge Hernández
Ney Costa
Jenny Vásquez
Maricela Durá

12:15 p.m. – 1:15 p.m.

1:15 p.m. – 1:35 p.m.
1:35 p.m. – 2:35 p.m.
2:35 p.m. – 3:35 p.m.

Discussion
Lunch
Round Table: Profitable and Nonprofitable Services: The
Experiences of LAC Agencies
APROFE
BEMFAM
CEMOPLAF
MEXFAM
PROSALUD

3:35 p.m. – 3:55 p.m.

Discussion

3:55 p.m. – 4:25 p.m.

Conclusions and Closing

Moderator: Daniel Aspilcueta,
INPPARES
Pablo Marangoni
Ney Costa
Teresa de Vargas
Maricela Durá
Martha Mérida

Alvaro Monroy, CMS
Teresa de Vargas, CEMOPLAF
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Appendix 4
ATTENDEE LIST: SUSTAINABILITY AND SOCIAL MISSION CONFERENCE
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Josefina Martínez
Enrique Suárez
Jesús Servin
José Alvarez Blas
Daniel Aspilcueta
Olenka Zapata
Gabriel Ojeda
Catalina Uribe
Magali Caram
Bienvenida Bobadilla
Martha Mérida
Jack Antelo
Ramiro Mayorga
Maria de Moya
Miguel Vela López
Julio Zabala
Elba Mercado
Rosa Rita Alvarez
Ramón Portes
Kirk Leach
Ing. Abastoflor
Cristian Schilling
John Bratt
Jim Foreit
Kris Lantis
Ricardo Vernon
Guy Stalworthy
Karen Foreit
Alvaro Monroy
Kell Wolfe
Ratha Logarthanan
Carlos Carrazana
Alan Forney
Ayyappan M.
Marco Egas

Institution
ADS
ADS
APROFAM
ASECSA
RENACIMIENTO
ASHONPLAFA
ASHONPLAFA
BEMFAM
BEMFAM
CELSAM
MEXFAM
MEXFAM
FEMAP
FEMAP
CHSP
INPPARES
INPPARES
PROFAMILIA Colombia
PROFAMILIA Colombia
PROFAMILIA Rep. Dominicana
PROFAMILIA Rep. Dominicana
PROSALUD
CIES
PROFAMILIA
CMS
MAXSALUD
APROPO
USAID
MUDE
ADOPLAFAM
INTERNATIONAL EYE FOUND.
INTERNATIONAL EYE FOUND.
INTI
FHI
FRONTIERS
FRONTIERS
FRONTIERS
PSI
TFGI
CMS
CMS
CMS
SUMMA FOUNDATION
HINDUSTAN LATEX
HINDUSTAN LATEX
SCHERING

E-mail
jorgeh@ads.org.sv
mercadeo@ads.org.sv
zaguilar@aprofam.org.gt

cmorlacchi@ashonplafa.com
rreyes@ashonplafa.com
info@bemfam.org.br
info@bemfam.org.br
developm@mexfam.org.mx
jmartínez@mexfam.org.mx
femap@infolink.net
femap@infolink.net
DASPILCU@INPPARES.org.pe
gojeda@profamilia.org.co
curibe@profamilia.org.co
profamilia@codetel.net.do
profamilia@codetel.net.do
jantelo@caoba.entelnet.bo

direjec@maxsalud.org.pe
emercado@usaid.gov
mude@centennialrd.net
adoplafa@tricom.net

jbratt@fhi.org
jforeit@pcdc.org
klantis@pcdc.org
rvernon@popcouncil.org.mx
guys@psieurope.org.uk
k.foreit@tfgi.com
amonroy@cmsproject.com
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Name
Institution
E-mail
Santiago Cordova
SCHERING
Cristopher Price
FPIA
Jesus Mendoza
FPIA
Julio Beingolea
VECINOS MUNDIALES
Isabel Stout
Catalyst Consortium Project
Marie France Semmelbeck Catalyst Consortium Project
msemmelbeck@rhcatalyst.org
Isabel Morales
Endowment Fund for Sustainab.
Luis Hernández
Endowment Fund for sustainab
Marguerite Farrell
USAID, LAC Bureau
Milo Schaub
CPR
Michael Kesserling
CPR
Julia Walsh
BIG
jwalsh@socrates.berkeley.edu
Deanna Gordon
BIG
gordon@are.berkeley.edu
Brian Mitchell
BIG
mitch4brian@hotmail.com
Nicole Buono
USAID Washington
Lisa Luchsinger
USAID Washington
lluchsinger@usaid.gov
Victoria Fuentes
UNFPA
Ernesto Pinto
CEMOPLAF
cemoplaf@uio.satnet.net
Teresa de Vargas
CEMOPLAF
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Carmen Acosta de Pozo CEMOPLAF
cemoplaf@uio.satnet.net
Rosario Naranjo
CEMOPLAF
cemoplaf@uio.satnet.net
Jenny Vasques
CEMOPLAF
Aida Haro
CEMOPLAF
Esmeralda Garcia
COLEGIO DE OBSTETRICES PICHINCHA
Miriam Becerra
APROFE
Agustín Cuesta
APROFE
Paolo Marangoni
APROFE
Pablo Palacios
JOHNS HOPKINS UNIVERSITY
Ivan Palacios
CARE
Nelson Oviedo
CEPAR
Margarita Quevedo
CORPORACION KIMIRINA
mquevedo@ecuanex.net.ec
Orlando Batallas
COF
Carolyn Benbow-Ross
UNFPA
Aída Lafebre
USAID
Roberto Goyes
CHRISTIAN CHILDREN FOUND
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Appendix 5
EVALUATION: SUSTAINABILITY AND SOCIAL MISSION CONFERENCE
TOTAL DE PARTICIPANTES EVALUADOS: 47
I. EVALUACIÓN A LA CONFERENCIA
1. Alcance de los objetivos
2. Contenido de la Conferencia
3. Estructura y secuencia
4. Profundidad
5. Utilidad y aplicación de los temas
II.
1.
2.
3.

5

4

3

2

1

5/4

Excelente

Muy Bueno

Bueno

Regular

Malo

Excelente/
Muy Bueno

18
21
21
11
16

24
21
19
27
25

5
5
5
9
5

19
18

6
11

EVALUACIÓN A LOS FACILITADOROS
Dominaron el tema
22
Capacidad didáctica
18
Forma en que propiciaron la
participación del grupo
20
Respondieron a las preguntas de los
participantes
19

15

11

21

7

III.
1.
2.
3.
4.

EVALUACIÓN DEL PARTICIPANTE
Adquirí habilidad y conocimientos
Me integré al grupo
Puse atención y participé
Demostré interés y esfuerzo

16
17
18
22

25
22
26
23

5
6
3
2

IV.
1.
2.
3.
4.
5.

EVALUACIÓN DE LOGÍSTICA
Calidad del material didáctico
Condiciones físicas y ambientales
Duración de la conferencia
Horario de la conferencia
Apoyo logístico

26
42
34
32
33

18
3
9
13
13

3
1
2
2
1

4.

2
1

89%
89%
85%
81%
87%
87%
77%

1

74%
85%

1
2

1

87%
83%
93%
96%
94%
96%
91%
96%
98%

SUGERENCIAS:
-

Felicitación – Gracias!
Ninguna – Felicitaciones
Excelente conferencia
Felicitaciones a CEMOPLAF
Continúen adelante
Gracias por la hospitalidad
En algunos temas sugiero mayor profundidad
Menos presentaciones y más grupos de
discusiones como el primer día
Volver a organizar otra conferencia con más
participación del grupo
En otra conferencia pedir la participación directa
de las ONGs que aportan con ayuda económica
Publicar los resultados
Thank you for the excellent translation! Thank
you!!

-

-

Favor de repartir las presentaciones antes de las
ponencias pues permite hacer anotaciones
coherentes y oportunas. ¡Gracias por tanta
amabilidad al personal de apoyo!
Dar secuencia para nuevas reuniones para
intercambio de experiencias
Quizá muy apretada la agenda
Agradecimiento por el evento tan importante en
organización, contenido y objetivos
Hacerla en 2 años, profundizar en la reducción
de costos. Excelente conferencia
Felicitaciones y realizar la próxima conferencia
CEMOPLAF did an outstanding job with
organization, I only wish there had been more
direct contact before and concerning logistics.
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Appendix 6
LIST OF PRESENTATIONS: SUSTAINABILITY AND SOCIAL MISSION
CONFERENCE
TITLE
Sustainabilty

PRESENTER, ORGANIZATION
Alvaro Monroy, CMS

La Sustentabilidad y la Misión Social

Guy Stalworthy, PSI/Europe

Sector Privado Misión Social

Santiago Córdova, CELSAM

Sustentabilidad y Misión Social: Desafíos para
las ONGs y el Sector Comercial

Karen Foreit, TFGI

Como Definen las ONG LAC la Misión
Social?

Catalina Uribe, PROFAMILIA-Columbia

Donantes y Fundaciones Privadas como una
Fuente de Financiamiento

Maricela Durá, MEXFAM

Perfile Socioeconómicos de los Clientes ONG
en Ecuador, El Salador, Guatemala y Honduras

John Bratt, FRONTIERS/FHI

Cuánto Necesitamos Incrementar los Precios
para Cambiar el Perfil de las Usuarias
Impacto de Actividades de Sustentabilidad
sobre Demand de Servicios y Perfil de
Usuarios de Planificación Familiar en
CEMOPLAF

Zonia Aguilar, APROFAM

Using Simple Survey Techniques to Set Prices
for Social Products and Services

Jim Foreit, FRONTIERS

Herramienta de Investigación de Mercado:
Segmentación Psicografica

Ratha Loganathan, CMS

Ernesto Pinto, CEMOPLAF

Herramienta de Investigación de Mercado: Una Martha Mérida, PROSALUD
Experiencia de PROSALUD
Análisis de Costos

Jesús Servín, FEMAP

A Profitability Analysis of the CEMOPLAF
Social Marketing Program

Rosario Naranjo, CEMOPLAF

When do cross-subsidies work?

Julia Walsh, BIG
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Estrategías y efectos de disminuir las
oportunidades perdids para prestar servicios de
salud reproductivo

Ricardo Vernon, FRONTIERS

Calidad con una estrategia de mercadeo

Mirriam Becerra & Agustín Cuesta, APROFE

Adding CM to NGO Activities: BEMFAM
expertise

Marcelo Mendonça, BEMFAM

Diversity beyond Reproductive Health

Deanna Gordon & Brian Mitchell, BIG

Selling to the Commercial Sector

Magali Caram, PROFAMILIA-Dominican
Republic

Accessing Credit and The Summa foundation

Carlos A. Carranzana, The SUMMA
Foundation

How can FPAs earn money out of the condom
business in order to finance other social
activities?

Michael Kesserling, CPR

Productos y Servicios Rentables y no
Rentables in ASHONPLAFA

Carlos Morlacchi, ASHONPLAFA

Productos y Servicios Rentables y no
Rentables

Ney Costa, BEMFAM

Productos y Servicios Rentables y no
Rentables: La experiencia de CEMOPLAF

Teresa de Vargas & Jenny Vásquez,
CEMOPLAF

Productos y Servicios Rentables y no
Rentables

Paolo Marangoni, APROFE

51

